Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-FAPI for advanced solid tumors (Phase 2, single-arm)
ChiCTR2600129027Phase 2Not yet recruiting
- Sponsor
- Affiliated Hospital of Inner Mongolia Medical University
- Start
- Jul 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 177Lu-DOTA-FAPI in Non-hematologic malignancy, sponsored by Affiliated Hospital of Inner Mongolia Medical University. Primary endpoints: Incidence of adverse events by grade, Dose-limiting toxicity (DLT) and 1 more. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
177Lu-DOTA-FAPI
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on ChiCTR2600129027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129027.